Clinical Trial

Forecasting Occult liveR Metastasis Using an Exosomal Signature for Intelligent Guided Hepatic Targeting

Study acronym: FORESIGHT
Completed
View on ClinicalTrials.gov →
Summary
Early liver metastasis (Early-LiM) is the most significant prognostic factor in pancreatic ductal adenocarcinoma (PDAC) and is thought to originate from occult micrometastases present at the time of surgery. Reliable preoperative detection of such lesions remains an unmet clinical need. The EXELiM study aims to develop and validate a circulating exosomal microRNA (exo-miRNA)-based liquid biopsy assay to accurately identify PDAC patients at high risk of occult liver metastasis before surgery. By integrating machine learning with multi-institutional plasma exosome profiling, this study seeks to enable biology-driven patient stratification and guide treatment sequencing toward precision oncology.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-11-03; most recent amendment 2026-03-11.
Status change: Recruiting → Completed 2026-03-11
Trial Details
NCT Number NCT07224802
Lead Sponsor City of Hope Medical Center
Conditions PDAC - Pancreatic Ductal Adenocarcinoma
Enrollment 372 participants
Start Date 2024-06-21
Primary Completion 2026-01-18 (estimated)
Study Completion 2026-02-18 (estimated)
Updated on ClinicalTrials.gov 2026-03-13